Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

Active, not recruitingOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 8, 2025

Study Completion Date

June 1, 2026

Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
DRUG

Pomalidomide

Oral pomalidomide up to 4 mg daily

Trial Locations (11)

19104

University of Pennsylvania, Philadelphia

21218

Johns Hopkins University, Baltimore

27599

University of North Carolina, Chapel HIll, Chapel Hill

32610

University of Florida, Gainesville

44195

Cleveland Clinic, Cleveland

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

84112

University of Utah, Salt Lake City

92093

University of California-San Diego, San Diego

94143

University of California-San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

University of Utah

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

University of Florida

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

University of Pennsylvania

OTHER

lead

Massachusetts General Hospital

OTHER

NCT07018401 - Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study | Biotech Hunter | Biotech Hunter